RT Journal Article
T1 Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort.
A1 Koirala, S
A1 Borisov, S
A1 Danila, E
A1 Mariandyshev, A
A1 Shrestha, B
A1 Lukhele, N
A1 Dalcolmo, M
A1 Shakya, S R
A1 Miliauskas, S
A1 Kuksa, L
A1 Manga, S
A1 Aleksa, A
A1 Denholm, J T
A1 Khadka, H B
A1 Skrahina, A
A1 Diktanas, S
A1 Ferrarese, M
A1 Bruchfeld, J
A1 Koleva, A
A1 Piubello, A
A1 Koirala, G S
A1 Udwadia, Z F
A1 Palmero, D J
A1 Munoz-Torrico, M
A1 Gc, R
A1 Gualano, G
A1 Grecu, V I
A1 Motta, I
A1 Papavasileiou, A
A1 Li, Y
A1 Hoefsloot, W
A1 Kunst, H
A1 Mazza-Stalder, J
A1 Payen, M-C
A1 Akkerman, O W
A1 Bernal, E
A1 Manfrin, V
A1 Matteelli, A
A1 Mustafa Hamdan, H
A1 Nieto Marcos, M
A1 Cadiñanos Loidi, J
A1 Cebrian Gallardo, J J
A1 Duarte, R
A1 Escobar Salinas, N
A1 Gomez Rosso, R
A1 Laniado-Laborín, R
A1 Martínez Robles, E
A1 Quirós Fernandez, S
A1 Rendon, A
A1 Solovic, I
A1 Tadolini, M
A1 Viggiani, P
A1 Belilovski, E
A1 Boeree, M J
A1 Cai, Q
A1 Davidavičienė, E
A1 Forsman, L D
A1 De Los Rios, J
A1 Drakšienė, J
A1 Duga, A
A1 Elamin, S E
A1 Filippov, A
A1 Garcia, A
A1 Gaudiesiute, I
A1 Gavazova, B
A1 Gayoso, R
A1 Gruslys, V
A1 Jonsson, J
A1 Khimova, E
A1 Madonsela, G
A1 Magis-Escurra, C
A1 Marchese, V
A1 Matei, M
A1 Moschos, C
A1 Nakčerienė, B
A1 Nicod, L
A1 Palmieri, F
A1 Pontarelli, A
A1 Šmite, A
A1 Souleymane, M B
A1 Vescovo, M
A1 Zablockis, R
A1 Zhurkin, D
A1 Alffenaar, J-W
A1 Caminero, J A
A1 Codecasa, L R
A1 García-García, J-M
A1 Esposito, S
A1 Saderi, L
A1 Spanevello, A
A1 Visca, D
A1 Tiberi, S
A1 Pontali, E
A1 Centis, R
A1 D'Ambrosio, L
A1 van den Boom, M
A1 Sotgiu, G
A1 Migliori, G B
K1 Bedaquiline
K1 Delamanid
K1 MDR-TB
K1 Prevention of TB sequelae
K1 Treatment outcomes
K1 Tuberculosis
AB The World Health Organization (WHO) recommends countries introduce new anti-TB drugs in the treatment of multidrug-resistant tuberculosis. The aim of the study is to prospectively evaluate the effectiveness of bedaquiline (and/or delamanid)- containing regimens in a large cohort of consecutive TB patients treated globally. This observational, prospective study is based on data collected and provided by Global Tuberculosis Network (GTN) centres and analysed twice a year. All consecutive patients (including children/adolescents) treated with bedaquiline and/or delamanid were enrolled, and managed according to WHO and national guidelines. Overall, 52 centres from 29 countries/regions in all continents reported 883 patients as of January 31st 2021, 24/29 countries/regions providing data on 100% of their consecutive patients (10-80% in the remaining 5 countries). The drug-resistance pattern of the patients was severe (>30% with extensively drug-resistant -TB; median number of resistant drugs 5 (3-7) in the overall cohort and 6 (4-8) among patients with a final outcome). For the patients with a final outcome (477/883, 54.0%) the median (IQR) number of months of anti-TB treatment was 18 (13-23) (in days 553 (385-678)). The proportion of patients achieving sputum smear and culture conversion ranged from 93.4% and 92.8% respectively (whole cohort) to 89.3% and 88.8% respectively (patients with a final outcome), a median (IQR) time to sputum smear and culture conversion of 58 (30-90) days for the whole cohort and 60 (30-100) for patients with a final outcome and, respectively, of 55 (30-90) and 60 (30-90) days for culture conversion. Of 383 patients treated with bedaquiline but not delamanid, 284 (74.2%) achieved treatment success, while 25 (6.5%) died, 11 (2.9%) failed and 63 (16.5%) were lost to follow-up.
YR 2021
FD 2021-03-19
LK https://hdl.handle.net/10668/26663
UL https://hdl.handle.net/10668/26663
LA en
DS RISalud
RD Apr 12, 2025